EKF Diagnostics Holdings plc

("EKF" or "the Company")

Result of General Meeting

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, announces that at the General Meeting held earlier today all resolutions were duly passed. The passing of the resolutions will enable the Company to proceed with:

·       The acquisition of Stanbio Laboratory L.P. which is conditional, inter alia, on Admission of the Consideration Shares; and

·       The allotment of the Placing Shares, to raise gross proceeds of £13 million.

The Company has made an application to the London Stock Exchange and it is expected that Admission of the Consideration Shares and the Placing Shares will take place on 16 June 2011.

Following Admission, the Company will have a single class of shares being Ordinary Shares of 1 pence each and there will be 249,978,134 Ordinary Shares in issue, each carrying one vote per Ordinary Share. The Company does not hold any Ordinary Shares in treasury. The total number of voting rights in the Company's Ordinary Shares will be 249,978,134 and this number may be used by shareholders as the denominator in calculations to determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Services Authority's Disclosure and Transparency Rules.

Definitions in this announcement are consistent with those set out in the Circular issued to shareholders of the Company and dated 23 May 2011, a copy of which is available on the Company's website.

Enquiries:

Notes to the Editor:

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated two further acquisitions, Quotient Diagnostics Limited ("Quotient"), in October 2010, for a maximum total consideration of £5.41m and Argutus Medical Limited, in December 2010, for £2.18m.

The Group, with its head office in Cardiff and operations in London, Germany, Poland, Russia and Ireland, is a leading diagnostics business, focused on the development, production and distribution of analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c. Recently, the Group has been granted SFDA approval in China for its Quo-Test HbA1c proprietary platform. With this approval, Quotient will be able to commence the promotion, distribution and sale of its Quo-Test HbA1c reagent kit on its proprietary platform in China.